Skip to content

aTyr Pharma ATYR Net Investment in Lease

Net Investment in Lease at other companies

Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
Vor Biopharma logo
Vor BiopharmaVOR
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's net investment in lease?
aTyr Pharma (ATYR) reported net investment in lease of $5.44M in Q1 2026.
How has aTyr Pharma's net investment in lease changed year-over-year?
aTyr Pharma's net investment in lease decreased by 5.4% year-over-year, from $5.75M to $5.44M.
What is the long-term trend for aTyr Pharma's net investment in lease?
Over 5 years (2020 to 2025), aTyr Pharma's net investment in lease has grown at a 21.5% compound annual growth rate (CAGR), from $2.08M to $5.52M.